Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

(2009) Evan A. Stein et al.   AMERICAN JOURNAL OF CARDIOLOGY

Long-term Benefit of High-Density Lipoprotein Cholesterol–Raising Therapy With Bezafibrate

(2009) Ilan Goldenberg et al.   ARCHIVES OF INTERNAL MEDICINE

Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters

(2009) W. Sean Davidson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Advanced Age, Antithrombotic Strategy, and Bleeding in Non–ST-Segment Elevation Acute Coronary Syndromes

(2009) Renato D. Lopes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins

(2008) Stefania Lamon-Fava et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Of Mice and Men

(2008) G.F. Watts et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice

(2008) José W.A. van der Hoorn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway

(2008) Giovanna Catalano et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

(2008) Fergus McTaggart et al.   CARDIOVASCULAR DRUGS AND THERAPY

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity

(2008) Menno Vergeer et al.   CIRCULATION

Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome

(2008) Pattie S. Green et al.   CIRCULATION

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

(2008) Stephen J. Nicholls et al.   CIRCULATION

Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque

(2008) James A. Shaw et al.   CIRCULATION RESEARCH

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2008) R. Scott et al.   DIABETES CARE

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels

(2008) D J Hausenloy et al.   HEART

Molecular processes that handle — and mishandle — dietary lipids

(2008) Kevin Jon Williams   JOURNAL OF CLINICAL INVESTIGATION

Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL

(2008) Lin-Hua Zhang et al.   JOURNAL OF LIPID RESEARCH

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

(2008) Wim A. van der Steeg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Is raising HDL a futile strategy for atheroprotection?

(2008) Tisha Joy et al.   NATURE REVIEWS DRUG DISCOVERY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

(2008) Frank Hermann et al.   THROMBOSIS RESEARCH

Spotlight on HDL-raising therapies: insights from the torcetrapib trials

(2008) Anatol Kontush et al.   Nature clinical practice. Cardiovascular medicine

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

(2007) John F. Paolini et al.   AMERICAN JOURNAL OF CARDIOLOGY

Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia

(2007) Maryse Guerin et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?

(2007) Philip J. Barter et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY